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 STUDY PROTOCOL Open Access
A multicentre randomised controlled trial
evaluating lactobacilli and bifidobacteria in the
prevention of antibiotic-associated diarrhoea in
older people admitted to hospital: the PLACIDE
study protocol
Stephen J Allen1,6*, Kathie Wareham2, Caroline Bradley3, Wyn Harris4, Anjan Dhar3, Helga Brown3, Alwyn Foden3,
Way Yee Cheung1, Michael B Gravenor1, Sue Plummer5, Ceri J Phillips1 and Dietrich Mack1
Abstract
Background: Antibiotic associated diarrhoea complicates 5–39% of courses of antibiotic treatment. Major risk
factors are increased age and admission to hospital. Of particular importance is C. difficile associated diarrhoea
which occurs in about 4% of antibiotic courses and may result in severe illness, death and high healthcare costs.
The emergence of the more virulent 027 strain of C. difficile has further heightened concerns. Probiotics may
prevent antibiotic associated diarrhoea by several mechanisms including colonization resistance through
maintaining a healthy gut flora.
Methods: This study aims to test the hypothesis that administration of a probiotic comprising two strains of
lactobacilli and two strains of bifidobacteria alongside antibiotic treatment prevents antibiotic associated diarrhoea.
We have designed a prospective, parallel group trial where people aged 65 years or more admitted to hospital and
receiving one or more antibiotics are randomly allocated to receive either one capsule of the probiotic or a
matching placebo daily for 21 days. The primary outcomes are the frequency of antibiotic associated and C. difficile
diarrhoea during 8–12 weeks follow-up. To directly inform routine clinical practice, we will recruit a sufficient
number of patients to demonstrate a 50% reduction in the frequency of C. difficile diarrhoea with a power of 80%.
To maximize the generalizability of our findings and in view of the well-established safety record of probiotics, we
will recruit a broad range of medical and surgical in-patients from two different health regions within the UK.
Discussion: Antibiotic associated diarrhoea constitutes a significant health burden. In particular, current measures to
prevent and control C. difficile diarrhoea are expensive and disrupt clinical care. This trial may have considerable
significance for the prevention of antibiotic associated diarrhoea in hospitals.
Trial registration: International Standard Randomised Controlled Trial Number Register ISRCTN70017204.
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Background
Antibiotic-associated diarrhoea (AAD) is diarrhoea that
occurs in association with antibiotic treatment and without
an alternative cause [1]. It is estimated to occur in 5 – 39%
of people taking antibiotics during or up to 12 weeks after
treatment [2]. AAD varies markedly in severity from mild
diarrhoea to severe diarrhoea as part of a life-threatening
illness caused by the anaerobic bacterium Clostridium
difficile (Clostridium difficile associated diarrhoea; CDAD)
which accounts for 15–39% of cases of AAD [3]. A par-
ticular concern is the emergence of the hypervirulent ribo-
type 027 strain of C. difficile documented in Canada, USA
and Europe [4]. Even mild diarrhoea may cause significant
morbidity and prolong hospital stay. The annual health-
care cost of CDAD in the USA was estimated to be more
than $3 billion [5,6].
Host risk factors for AAD include advanced age, im-
mune suppression, gastrointestinal disease or previous
gastrointestinal surgery and severe co-morbidity [2,3,7].
AAD can complicate treatment with any antibiotic but
broad spectrum antibiotics (clindamycin, cephalosporins,
β-lactamase resistant penicillins, quinolones), antibiotic
combinations and repeated or long treatment courses are
associated with the greatest risk of AAD [2,7]. Other envir-
onmental factors include admission to hospital, longer
duration of stay and use of naso-gastric tubes [8]. Suppres-
sion of gastric acid may also be an additional risk factor
for CDAD in both hospital inpatients [9] and people in the
community [10].
Antibiotics may result in diarrhoea through several
mechanisms. Antibiotic disruption of the commensal gut
microorganisms results in osmotic or secretory diarrhoea
from changes in carbohydrate, short chain fatty acid and
bile acid metabolism and impaired colonization resistance
allowing a competitive growth advantage to diarrhoeagenic
organisms [11-13].
Given the frequency and potential severity of CDAD,
extensive and costly strategies for the prevention of AAD
have become an established part of hospital in-patient
management. These include strict limitations on the use of
antibiotics, hand washing, isolation of diarrhoea patients
and decontamination of the environment [14]. However,
despite these efforts, the heat- and drying-resistant spores
of C. difficile persist in the modern hospital environment
[15,16].
In view of the mechanisms underlying AAD, probiotics
offer a potential means of prevention. Probiotics are defined
as live microbial organisms which, when administered in
adequate numbers, are beneficial to health [17]. In a recent
meta-analysis, McFarland [18] pooled data from 25 RCTs
(total of 2,810 adults and children) and reported a reduced
relative risk of AAD in participants receiving a probiotic
(0.43; 95% CI 0.31 – 0.58). Trials of many different single
strains of probiotic bacteria, the yeast Saccharomyces
boulardii (S. boulardii), probiotic mixtures and probiotic and
prebiotic mixtures were included in this analysis. Dosage
(number of organisms) also varied markedly between studies.
In sub-group analyses, factors associated with greater efficacy
in preventing AAD were use of S. boulardii or Lactobacillus
rhamnosus (L. rhamnosus) GG, mixtures of probiotics and
preparations with high numbers of organisms.
Members of our research group [19] assessed the effect of
a combination of L. acidophilus and B. bifidum on CDAD
in a pilot study in elderly patients receiving antibiotics.
Overall, 30/138 (22%) patients developed diarrhoea with
5/69 in the placebo group and 2/69 in the probiotic group
testing positive for C. difficile toxin. In this small study, the
main effect of the intervention appeared to be neutralisa-
tion of the toxin rather than prevention of colonization with
C. difficile. The meta-analysis by McFarland [18] included 5
studies, in addition to our study, but all of these were treat-
ment trials of patients with established or recurrent CDAD.
When designing our study, apart from a small trial with few
CDAD cases [20], we were not aware of other studies that
had assessed probiotics in the primary prevention of CDAD
in hospitalized adults. Since then, reports of trials have been
consistent with the prevention of CDAD by lactobacilli and
bifidobacteria although relatively small numbers of partici-
pants were recruited [21,22].
Probiotics were classified by the US Food and Drug
Administration in 2002 (notice GRN 000049) as “generally
regarded as safe”. Reported adverse events in research
studies were mild but occurred with S. boulardii (constipa-
tion, increased thirst) and L. rhamnosus GG (bloating, gas)
[18]. Probiotics have been administered without adverse
effects to vulnerable groups such as children and adults
with HIV infection and preterm infants [23]. However, an
expert group in the USA concluded recently that although
the available evidence from randomised trials did not indi-
cate a widespread risk of adverse events, researchers
should monitor and quantify adverse events in future pro-
biotic intervention studies [24].
In summary, a variety of probiotics appear to reduce the
risk of AAD. However, the large number of different pro-
biotics and different regimens that have been evaluated
compromises the development of clinical practice guide-
lines. Also, many trials have included only a small number
of participants, trial methods have often been poor, the
period of follow-up limited and the quality control of the
probiotic interventions has been inadequate [25]. There are
insufficient data to assess the effectiveness of probiotics in
the prevention of CDAD.
Presentation of the hypothesis
In older people admitted to hospital and treated with
one or more antibiotics, administration of a multi-strain
probiotic would reduce the frequency of AAD and
CDAD.
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Testing the hypothesis
This study is a double-blind, randomized, parallel group,
placebo-controlled trial. We plan to recruit patients with a
wide range and severity of illness from as many wards as
possible in 5 secondary care hospitals from 2 geographic-
ally distant UK health authorities, in order to be confident
that our findings are applicable to a diverse range of older
patients admitted to National Health Service (NHS) hospi-
tals and similar institutions. Planned recruitment sites in
the Abertawe Bro Morgannwg University Health Board
(ABMUHB), South West Wales are Singleton and Morris-
ton hospitals (total 1450 beds), and in the County Durham
and Darlington Foundation NHS Trust (CDDFT), Univer-
sity Hospital of North Durham, Bishop Auckland General
Hospital and Darlington Memorial Hospital (1353 beds).
In 2005/6 (12 months), 26,692 people aged ≥65 years were
admitted in Swansea and 21,676 in CDDFT and approxi-
mately one third received antibiotics.
Inclusion and exclusion criteria are shown in Table 1.
Exclusion criteria will be limited to possible contraindica-
tions to probiotics identified in previous studies and case
reports [23]. In particular, following the findings of the
PROPATRIA trial [26], we will exclude patients with se-
vere illness requiring high dependency or intensive care
(but not planned admission to these facilities for observa-
tion only), acute pancreatitis, any known abnormality or
disease compromising intestinal blood supply, and those
with a jejunal tube in situ or receiving jejunal feeds.
The investigational medicinal products (IMPs) will be
discontinued and participants withdrawn from the study
if they develop pancreatitis or severe illness that requires
high dependency or intensive care. However, these parti-
cipants will be included in intention-to-treat analysis.
The flow chart regarding screening, recruiting and follow-
ing-up participants is shown in Figure 1. A research nurse
will take signed, informed consent according to standard
guidelines [27]. It is expected that some potential partici-
pants will not be able to give informed consent because of
impaired mental capacity. Assent will be sought from next
of kin, other relatives or carers in line with Article 5 of the
EU Directive 2001/20/EC (Clinical Trials on incapacitated
adults not able to give informed legal consent). The consent
form will be held in the investigator file, with copies filed in
the hospital notes and given to the participant. A sticker
will be placed on the hospital notes and the patient’s Gen-
eral Practitioner informed by letter. The reasons for declin-
ing to participate, if provided, will be recorded.
Demographic and clinical data will be recorded at re-
cruitment and include the type and dose of antibiotics and
other potential risk factors for AAD or CDAD (Table 2).
Generation and concealment of a random allocation sequence
A random allocation sequence using blocks of variable
sizes will be produced using SAS PROC PLAN Version
9.1 (SAS Institute Inc., Cary, NC, USA). The sequence
will allocate participants to either placebo or probiotic
on a 1:1 basis and be stratified by centre to ensure that
similar numbers of patients will be allocated to each arm
of the study in each centre. The allocation sequence will
not be available to members of the research team during
participant recruitment and follow-up.
Investigational medicinal products and participant
allocation to trial arms
The absence of a scientific rationale for selecting a par-
ticular strain and dosage of organisms for specific health
outcomes is reflected in the many different probiotic
preparations evaluated in the prevention of antibiotic-
associated diarrhea [28]. However, the use a combination
of different organisms with large numbers of each strain
is likely to maximize gut colonization and, thereby,
colonization resistance. To minimise the risk of adverse
effects such as systemic infection, we decided not to con-
sider S. boulardii or other organisms that are not part of
the normal human commensal flora.
Based on evidence of ability to survive passage
through the upper gut, adherence to intestinal mucosa,
excellent viability at the point of administration, our
earlier study [19], and evidence that L. acidophilus
neutralises C. difficile toxin in an epithelial cell assay
in vitro (SP pers. comms), we selected a probiotic
comprised of two strains of L. acidophilus (CUL60,
Table 1 Criteria for participant inclusion and exclusion
Inclusion criteria
• people aged ≥65 years and admitted to hospital
• exposed to one or more antibiotics within the last
7 days or are about to start antibiotic treatment
• consultant approval to invite patient to join
the study
Exclusion criteria
• diarrhoea present1
• immunocompromise2
• severe illness requiring high dependency or
intensive care3
• prosthetic heart valve
• C. difficile in past 3 months
• active inflammatory bowel disease4
• suspected acute pancreatitis5
• known compromised gut blood supply6
• jejunal tube in situ or receiving jejunal feeds
• previous adverse reaction to probiotics
• unwilling to discontinue exiting use of probiotics
1Defined as 3 or more watery or loose stools (Bristol Stool Form Scale types
5–7) in a 24 h period. 2Sufficient to require isolation and barrier nursing.
3Planned admission to these facilities for observation only is not an exclusion
criteria. 4Required specific treatment in past 12 months. 5Abdominal pain with
serum amylase/lipase > ×3 institutional upper limit of normal. 6Abnormality or
disease of mesenteric vessels or coeliac axis.
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National Collection of Industrial, Food and Marine
Bacteria [NCIMB] 30157 and CUL21, NCIMB 30156),
Bifidobacterium bifidum (B. bifidum; CUL20, NCIMB
30153) and B. lactis (CUL34, NCIMB 30172). The pro-
biotic is prepared as lyophilised powder in a vegetarian
capsule containing a total of 6 x 1010 organisms/capsule.
These organisms are commercially available through
BioCare, UK and Pharmax, USA. The placebo is an
identical capsule containing inert maltodextrin powder.
The dosage is 1 capsule/day taken with food and, where
possible, between antibiotic doses, for 21 days.
To comply with labeling requirements, Obsidian
Research Ltd., UK will prepare bottles labeled with each
unique study number in the series and containing 21
capsules of the appropriate IMP according to the random
allocation sequence. The research nurse will allocate each
participant sequentially to the next unique study number
in the sequence and provide them with the corresponding
IMP bottle. The participant will be instructed to take
the first dose of the IMP on the day of recruitment. The
daily administration of the IMP will be supervised by
the research nurses in ABMUHB and by the
ward nurses in CDDFT during hospital admission and
participants will be encouraged to complete the course
once discharged.
The process for acquiring a license for provision of the
IMPs was begun in March 2008 and a Medicines and
Healthcare products Regulatory Agency (MHRA) inspector
notified in April 2008. The MHRA inspected the facility
responsible for the packaging and quality control of the
IMPs and the license was granted in November 2008. We
had underestimated the time required for MHRA approval
and this resulted in a delay in starting participant
recruitment.
To ensure the quality of the probiotic, organism
identity will be checked by established molecular
techniques and viability by quantitative bacterial culture
in study preparations retrieved from wards during the
study. This will be done by an independent laboratory to
maintain masking of the allocation sequence. In vitro
antibiotic testing demonstrated that the probiotic bacteria
were generally sensitive to broad spectrum antibiotics and
all four strains were sensitive to ceftriaxone, chloram-
phenicol, erythromycin, linezolid and tetracycline.
Follow-up
Research nurses will review participants daily during
admission to determine the onset, frequency and duration
of any diarrhoea and ask about gastrointestinal symptoms
(abdominal pain, bloating, flatus, nausea), acceptability and
Figure 1 Participant flow chart. Notes: 1. ABMUHB – Abertawe Bro Morgannwg University Health Board; CDDFT – County Durham and
Darlington NHS Foundation Trust. 2. The patient or next of kin is approached for consent in the afternoon if verbal and written information about
the trial is provided in the morning, or the following day if provided in the afternoon. 3. Investigational medicinal product; either 21 capsules of
probiotic or placebo.
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adverse effects of the interventions. After discharge,
follow-up will be weekly by telephone call, postal
questionnaire or home visit as appropriate. Participants
will be provided with contact details for ready telephone
access to research staff to notify the onset of diarrhoea or
adverse events. All participants will be followed-up for
8 weeks after completing antibiotic treatment to a max-
imum of 12 weeks from recruitment for those on longer
antibiotic courses.
Outcome measures
The two outcomes used to generate the sample size, AAD
and CDAD, have been identified as co-primary outcomes
(Table 3). Diarrhoea is defined as 3 or more loose stools in
a 24 h period. We will use the Bristol Stool Form Scale
[29] to assist participants in describing stool consistency;
types 5-7 will be consistent with diarrhoea.
All participants who develop diarrhoea during the
study period will be asked to provide a stool sample and
this will be collected during a home visit if required. The
cause of diarrhoea will be determined by NHS laborator-
ies according to their usual practice. Stools will be ana-
lysed for diarrhoeal pathogens (bacterial culture for
Salmonella sp, Shigella sp, Campylobacter, E. Coli 0157;
wet film for ova, cysts and parasites) and for C. difficile
toxins. In ABMUHB, C. difficile will be identified by an
in-house culture assay with further analysis by Meridian
Premier Toxin A+B Enzyme Immunoassay (Meridian
Bioscience Europe Inc., Cincinnati, USA) if required. In
CDDFT, toxins are identified using the mini VIDAS sys-
tem (C. diff Quik Check, Techlab, Blacksburg, U.S.A.). If
a cause of the diarrhoea is not identified, a further stool
sample will be collected and tested 2 days later.
For the primary outcome measures, AAD is defined as
diarrhoea without pathogens detected on routine laboratory
analysis, negative for C. difficile toxin and without alternative
cause (e.g. laxative treatment). CDAD is defined as diarrhoea
with stools positive for C. difficile A or B toxin. For quality
control purposes, C. difficile culture and confirmation by im-
munoassay will be undertaken in 1 in 5C. difficile toxin posi-
tive stool samples collected in Swansea. In view of the
known inadequacies of current methods for the laboratory
diagnosis of C. difficile [30], we will also save stool samples
at −20°C from participants with diarrhoea for further testing
for the glutamate dehydrogenase antigen and also lactoferrin
(IBD scan and C. diff Quik Chek Complete; Alere Limited,
Stockport, UK). This may result in the diagnosis of CDAD
that was not detected by routine methods.
Table 2 Baseline demographic and clinic data and risk
factors for AAD
Variable Units or Categories where appropriate
• Age years
• Sex male; female
• Race white; black; Asian; Chinese; other
• Period of recruitment summer (May – Sept); winter (Oct-March)
• Smoking usual number of cigarettes/day
• Alcohol usual number of units/week
• Where admitted from home; residential care; other
hospital; other
• Admission type emergency/unplanned; elective/
planned for procedure or investigation
• Admission diagnosis or
main cause of admission
• Co-morbidity hypertension; asthma; diabetes; chronic
obstructive airways disease; renal disease;
irritable bowel syndrome; dementia;
Alzheimer’s disease; other
• Previous GI surgery
• Number of hospital
admissions in last eight weeks
• Antacid treatment antacid; H2-receptor antagonist; proton
pump inhibitor
• Naso-gastric tube in-situ
• Duration of hospital stay
prior to recruitment
days
• Indication for
antibiotic treatment
• Antibiotic treatment:
antibiotic used1
single class; 2 classes; 3 or more classes
• Antibiotic treatment:
total duration
single dose; 1–6 days; 7–13
days; ≥14 days
1Antibiotics will be classified according to British National Formulary categories
(www.bnf.org): Penicillins (sub-classified as benzylpenicillin, penicillinase resistant
penicillin, broad-spectrum penicillins, anti-pseudomonas penicillins);
Cephalosporins (sub-classified as 1st, 2nd and 3rd generation); Carbapenems and
other beta-lactams; Tetracyclines; Aminoglycosides; Macrolides; Clindamycin;
Sulphonamides and trimethoprim; Metronidazole; Quinolones; Glycopeptides; TB
drugs; other.
Table 3 Outcome measures
Primary outcomes
1. the occurrence of AAD
2. the occurrence of CDAD
Secondary outcomes
1. severity1 and duration of AAD
2. severity1,2 and duration of CDAD and
incidence of recurrence within the
8-12 weeks follow-up period
3. abdominal symptoms (abdominal pain,
bloating, flatus, nausea)
4. well-being and quality of life assessed
using the generic measures EQ-5D and
the York SF12 (Iglesias 2001) at recruitment
and 4 and 8 weeks
5. duration of hospital stay
6. serious adverse effects
7. acceptability of the probiotic preparation
8. viability of the probiotic at point
of administration
9. cost-effectiveness
1Frequency and consistency of stools. 2Additional information extracted from
the clinical records (e.g. laboratory parameters, findings at sigmoidoscopy,
pseudomembraneous colitis, colectomy, death).
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Participants who develop severe diarrhoea will be
investigated and managed according to the current practice
of their clinicians. We will extract information from the
clinical records (e.g. laboratory parameters, findings at sig-
moidoscopy, colectomy) to classify the severity of CDAD.
At the end of follow-up, participants will be classified as
either developing AAD, CDAD, another cause of diarrhoea
(e.g. norovirus) or no diarrhoea. Other endpoints have been
listed as secondary outcomes (Table 3).
Sample size and recruitment
Conservatively, we expected ADD to occur in 20% and
CDAD in 4% of participants allocated to the placebo
group [2]. To detect a 50% reduction in the frequency
CDAD in the probiotic group (i.e. 2% frequency) with
80% power at the 5% significance level, would require
2,478 subjects (1,239 in each group; 1:1 allocation). At
the 5% significance level, this number of participants
would provide a power of >99% to detect a 50% reduc-
tion in ADD (i.e. 10% frequency) and a power of 90% to
detect a 25% reduction in ADD (i.e. 15% frequency) in
the probiotic group. To allow for 10% drop-outs and
10% loss to follow-up due to deaths unrelated to diar-
rhoea, we plan to recruit 2,974 participants.
Based on data from 2005/6, about 14,000 patients per
year aged ≥65 years and exposed to antibiotics were admit-
ted to the study hospitals and there was a total of 963 cases
of CDAD. Conservatively, we expect to be able to recruit
between 1:9 and 1:10 of eligible patients (approximately 124
patients/month) and undertake recruitment for a total
of 24 months. This estimate was supported by a 2-week
pilot study of the recruitment process in 23 medical and
surgical wards in Morriston Hospital when research nurses
visited the wards daily. Out of a total of 253 admissions
aged ≥65 years, 166 patients were excluded (152 patients
had no current or planned exposure to antibiotics; 12
already had diarrhoea [including 1 CDAD]; 1 active inflam-
matory bowel disease; 1 reported a previous adverse reac-
tion to a probiotic). Eighty-seven (34.4%) patients were
eligible to participate in the pilot study but 8 of these were
either confused or not available (in theatre or undergoing
investigations). Therefore, the study design was explained
to 79 patients (31.2% of total admissions) and 58 (73.4%)
stated that they would have agreed to participate in this
study.
We will monitor the number of participants reaching
study endpoints in each hospital every 3 months. The eth-
ical permission secured for the study included all hospitals
within each health authority providing an ability to extend
recruitment if needed.
Statistical analysis
Primary outcomes will be analysed with standard methods
for a binary outcome. Risk difference and odds ratio
between two groups and their 95% confidence intervals for
AAD and CDAD will be estimated. In addition, covariate
adjustment analysis that includes the relevant covariates
(such as age, gender, specific antibiotic, centre) will be per-
formed. To explore whether prevention strategies should
be provided to all patients or just those at high risk of diar-
rhoea, we will assess probiotic efficacy according to known
or potential risk factors for AAD and CDAD as described
previously. Sub-group effects will be identified by inspec-
tion of interaction terms, and these will be interpreted in
light of power relative to main effects and supporting evi-
dence of mechanism [31]. All analyses will be performed
using SAS PROC PLAN Version 9.1 (SAS Institute Inc.,
Cary, NC, USA).
There are few tools that are validated for measuring
QoL in older people and none specifically targeted at
treatment-induced diarrhoea. We will use the generic
measures EQ-5D and the York SF12 [32] to understand
the broader health impact related to treatment-induced
diarrhoea and facilitate cost-effectiveness analysis.
Health economic analysis will be undertaken from the
perspective of the UK NHS. Resources utilised by each par-
ticipant will include the cost of the probiotics, staff time
involved in administering probiotics, treatment of adverse
events, assessment of cases of diarrhoea (stool collection
and culture/toxin assay, endoscopy) and the costs of dealing
with and treating diarrhoea such as laundry, antibiotics,
increased hospital stay and co-morbidities. Unit costs will
be determined from discussion with relevant clinicians and
finance department staff as well as from recognised pub-
lished information.
Cost differences between the probiotic and placebo
group will be determined and used in conjunction with
differences in outcomes between groups in undertaking
a cost-consequences analysis. Cost per case of diarrhoea
averted will be the primary outcome measure. Sub-group
analyses will determine the relative cost-effectiveness of
preventative strategies in different risk groups. In addition,
a cost-utility analysis will be undertaken based on the
differences in costs between the two groups and in quality-
adjusted life years derived from responses to the EQ-5D
questionnaire.
Given the short timescale of the project, there will be no
discounting of the costs or benefits. Sensitivity analyses will
investigate the robustness of the results to changes in esti-
mated costs and outcomes and probabilistic sensitivity ana-
lysis will use bootstrap resampling to determine the
probability that preventive strategies are within certain
thresholds. The budgetary impact from a UK NHS perspec-
tive of adopting a policy of administering a probiotic prep-
aration to prevent or ameliorate AAD and CDAD in people
aged 65 years and over admitted to secondary care NHS
facilities and receiving oral or intravenous antibiotics will
also be assessed.
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Trial organisation and safety monitoring
The funders (the National Institute of Health Research
Health Technology Assessment [HTA] Programme) will
appoint the chairs and members for a Trial Steering
Committee (TSC) and an independent Data Monitoring
and Ethics Committee (DMEC). The DMEC will include
an independent statistician who will generate and hold
the random allocation sequence for the trial. Trial man-
agement will be centered in the Clinical Research Unit,
Morriston Hospital, Swansea. A Trial Management Com-
mittee will include the Principle Investigator, the Project
Manager, the CDDFT Site Co-ordinator and CDDFT
hospital site leads.
In view of the expected high frequency of adverse events
in an elderly population of hospital in-patients, the record-
ing of gastro-intestinal symptoms during follow-up and
the excellent safety record of probiotics, only information
regarding serious adverse events (SAEs) will be recorded.
SAEs will be defined and reported according to GCP
guidelines [27], assessed by the local research clinicians
involved in the project as to their attribution and reviewed
regularly by an Independent Safety Monitor.
Suspected Unexpected Serious Adverse Reactions
(SUSARs) will be defined as the development of:
1. bacterial infection (any manifestation of infection:
abscess, bacterial endocarditis, bacteraemia etc.)
where a lactobacillus or bifidobacteria is isolated in
pathological specimens
2. multi-organ failure
3. bowel ischaemia
4. pancreatitis (abdominal pain with serum amylase or
lipase concentration ≥3 times the institutional upper
limit of normal)
SUSARs will be reported immediately to the Independ-
ent Safety Monitor to consider their attribution to the
participant’s inclusion in the trial. It was considered that
knowledge of a participant’s allocation would not inform
the clinical management of an SAE or SUSAR and,
therefore, procedures for the immediate unmasking of
participant allocation will not be established. If required,
unmasking could be undertaken by the Independent Sta-
tistician. The Independent Statistician will undertake an
unblinded, interim analysis of SAEs and SUSARs in the
first 500 participants with complete data and report the
findings to the DMEC.
Implications of the hypothesis
Current evidence is insufficient to inform the use of probio-
tics in the prevention of AAD and CDAD in routine clinical
practice. Recommendations for substantiating the health
effects of probiotics have been published [33,34]. We plan
to evaluate a multi-strain probiotic consisting of two strains
of lactobacilli and two strains of bifidobacteria in the pre-
vention of AAD. We plan to recruit a large number of
patients admitted to hospitals and receiving antibiotics in
the UK that will be representative of the population of hos-
pitalized older patients in industrialised countries. Causes of
diarrhoea will be assessed according to usual practice to
investigate the effectiveness and cost-effectiveness of this
intervention if it were implemented into routine practice.
The proposed study received ethics approval from the
Research Ethics Committee for Wales in November 2008
and from the NHS Research and Development Depart-
ments responsible for the hospital sites. Recruitment of
participants began in June 2009 in ABMUHB and October
2009 in CDDFT and is estimated to be completed by
March 2012. Published results are expected later in 2012.
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